Pfizer Corp - PFE Net earnings per share (EPS TTM)

Official company branding of Pfizer (PFE)

Pfizer Inc. (PFE) is updating its portfolio, replacing declining COVID vaccines with innovative oncology drugs. This strategy relies on aggressive M&A deals to shift its growth vector. Global distribution reach and capital allow the behemoth to acquire biotech startups, creating future monopolies. The TTM annual earnings per share illustrates this fundamental resilience, with the latest figure standing at 0.70.

PFE (Pfizer Inc.) Net earnings per share for the last four quarters history from 07/04/2022 to 11/10/2026

Analytical breakdowns for Pfizer Inc.

- current quotes and average value forecast:
Price Chart Pfizer Inc.|PFE - Price Target Chart
- issuer market value details:
Market Capitalization Pfizer Inc.|PFE - Business Value
- business book valuation details:
Book Value per Share Pfizer|PFE - Book Valuation of Business|Market Value to Book Value Ratio pfizer.com|PFE - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital Pfizer Inc.|PFE - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Pfizer Corporation|PFE - Company Aggregate Indebtedness|Debts to Book Capitalization Pfizer Inc.|PFE - Long-Term Liabilities|Company Short-Term Debts Pfizer|Quick Liquidity Indicator pfizer.com
- net income and valuation multiples indicators:
PFE - Profit After Tax|Projected Future Earnings Pfizer Inc.|PFE - Market Cap to Earnings|Future Price to Earnings Pfizer|PFE - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Pfizer Inc.|PFE - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Pfizer|PFE - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months pfizer.com|PFE - Earnings per share growth this year|Earnings growth forecast for next year Pfizer Inc.
Summary company analysis:Pfizer Inc. (PFE)
Manufactured products of Pfizer Corporation

This indicator measures the total net income of Pfizer Inc. (PFE) over the last four quarters, distributed per common share to determine the actual return on equity. By analyzing the annual net income per share trend, an investor assesses the resilience of the defensive business of Pfizer Inc. (PFE), where payment stability is ensured by patents and demand for drugs regardless of market conditions.

Key competitors

LLY - Earnings per share for the last twelve months|ABBV: Earnings per share for the last twelve months|AZN: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NVS|MRK (Merck Sharp & Dohme) - Net earnings per share (EPS TTM)|Novo Nordisk Group (NVO) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Amgen Inc. (AMGN)|sanofi.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) BMY (Bristol Myers Squibb)|Net earnings per share for the trailing year GlaxoSmithKline plc|TAK - Earnings per share for the last twelve months|Earnings per one share for the last 12 months TEVA|RDY: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months VTRS (viatris.com)|ROIV (Roivant Sciences) - Net earnings per share (EPS TTM)|Zai Lab Ltd (ZLAB) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months BHC (Valeant Pharmaceuticals)|COSM: Earnings per one share for the last 12 months